After a Tough 2021, RTW is Still Bullish

One of the hottest biopharma and life sciences funds in recent years is confident that it can rebound from last year’s setback.

Stephen Taub February 23, 2022

Andrey Rudakov/Bloomberg

The sharp selloff in fledgling biopharma and life sciences stocks in the past year or so has not spared RTW Investments. The fund was down more than 9 percent in 2021 and lost another 17.6 percent in January of this year.Even so, its recent setbacks

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.

Contact Info

New York
1270 Avenue of the Americas, Suite 1100
New York, NY 10020
P: +1 212 224 3300

London
4 Bouverie Street
London EC4Y 8AX
P: +44 207 779 8888

Hong Kong
Unit 2488, 24/F
Lee Garden One,
33 Hysan Avenue
Causeway Bay, Hong Kong
P: +852 2912 8001

Corporate

About Us

Leadership Team

Careers

II Press Room

Digital

Masthead

Thought Leadership

Display Advertising

Reprints

FAQs

Events

Events Calendar

Memberships

Subscription

Subscribe to Premium

Register

Register for Free Account

Newsletters

Sign up for II newsletters

© 2025 Institutional Investor LLC. All material subject to strictly enforced copyright laws. Please read our Terms & Conditions, Modern Slavery Act Transparency Statement, Accessibility Statement and Privacy Policy before using the site.

develop build:2025-12-18 Login